GSK (GSK) announced the European Commission’s, EC, approval of Shingrix in a prefilled syringe. The current vaccine presentation comprises two vials, one with a lyophilised powder antigen and another with a liquid adjuvant. The lyophilised powder antigen requires reconstitution, where the suspension in the adjuvant vial is withdrawn and injected into the antigen vial. The new prefilled syringe simplifies the vaccine administration process for healthcare professionals by removing the need to undertake these steps prior to administration.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK: Encouraging Bepirovirsen Data but Narrow Commercial Upside Supports Hold Rating
- Ionis partner GSK reports B-Well 1, B-Well 2 studies met primary endpoint
- GSK downgraded to Underweight from at Barclays on limited pipeline readouts
- GSK downgraded to Underweight from Equal Weight at Barclays
- GSK announces approval of Exdensur by Japan’s MHLW